Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism
Also known as: PAI-1 4G/5G Polymorphism, Plasminogen Activator Inhibitor (PAI-1), Gene Polymorphism
Use
Deep vein thrombosis (DVT) and coronary artery disease (CAD) are associated with increased PAI-1 levels. Elevated PAI-1 levels may help predict risk of reinfarction in survivors of myocardial infarction, particularly in young individuals. PAI-1 levels tend to be lower in individuals with 4G/5G or 5G/5G genotype compared to a 4G/4G genotype.
Special Instructions
Informed consent is required for New York patients.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Results of this test are for investigational purposes only. The result should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 52757-2
- 52757-2
- 77202-0
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
1 mL
Minimum Volume
Not provided
Container
Lavender-top (EDTA) tube or yellow-top (ACD) tube
Storage Instructions
Maintain specimen at room temperature. Stable at room temperature or refrigerated for eight days.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | eight days |
| Refrigerated | eight days |
Other tests from different labs that may be relevant